KO Client Nanospectra Closes $3 Million Series B-1 Financing
- KO Firm
- September 24, 2020
KO client Nanospectra Biosciences, a medical device company that is pioneering a novel use of nanomedicine to destroy tumors without damaging adjacent healthy tissue, recently closed a $3 million Series B-1 financing with total approved capital of up to $6 million.
The financing will be used for additional development and commercialization of Nanospectra’s lead product AuroLase®, which is the first and only ultra-focal ablation therapy designed to maximize treatment efficacy while minimizing side effects typically associated with surgery, radiation and alternative focal therapies.
Read more in Medical Device Network.